Guided Therapeutics Reports LuViva Device Detects Cervical Precancers Missed by Standard Care
Reuters
Dec 17, 2025
Guided <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports LuViva Device Detects Cervical Precancers Missed by Standard Care
Guided Therapeutics Inc. has announced preliminary findings from its FDA pivotal clinical trial evaluating the LuViva Advanced Cervical Scan, a device designed for rapid and painless cervical cancer detection using biophotonic technology. The initial results indicate that the current standard of care misses approximately 25% of early cervical precancer cases among women referred for biopsy following abnormal Pap and/or HPV results. The LuViva device aims to improve detection rates of these cases. The completed study enrolled approximately 480 subjects, with over 420 to be evaluated for efficacy, meeting FDA-reviewed protocol criteria. Final clinical results are expected to be filed with the FDA within the next 30 to 60 days. Results from the study have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guided Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217768018) on December 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.